Business, energy, technology, markets and global industry news from Business News Today

Skip to content

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

Perfuse Therapeutics

PharmaDeviceNews Perfuse Therapeutics

Representative image: Bayer’s planned Perfuse Therapeutics acquisition highlights the intensifying race to develop next-generation ophthalmology treatments beyond Eylea, with PER-001 adding a potential new pathway for glaucoma and diabetic retinopathy innovation.

Pharma & Biotech

Inside Bayer’s $2.45bn push to defend its ophthalmology franchise

by Pallavi Madhiraju
May 9, 2026
0 Comments

Eylea is under pressure. Bayer’s $2.45bn Perfuse bet tests whether PER-001 can carry its next ophthalmology growth story.

Read More

Latest news and features

NewAmsterdam Pharma and Menarini win EU approval for Ubeslo and Evlarco
AMT-130 four-year data extend Huntington’s disease signal as FDA evaluates uniQure BLA
Novo Nordisk bets up to $2.6bn on Hengrui’s once-weekly oral GLP-1/GIP drug
Evorpacept biomarker signal deepens in HER2-positive gastric cancer as ALX Oncology shifts focus
Teva wins FDA approval for DEGEVMA biosimilar across all Xgeva indications
One Carvykti infusion, five years without maintenance: Johnson & Johnson’s tiny trial delivers a striking myeloma signal
MediciNova stock up 85% in September as pivotal ALS trial reaches final patient visit
Merck KGaA’s $11.3bn Bio-Techne deal clears shareholder vote as life-science tools consolidation advances
FDA sets January decision for Pharming Group’s lower-dose Joenja pediatric expansion
Five-year CARVYKTI data deepen evidence for durable remission in earlier-line multiple myeloma
Eli Lilly just cut basal insulin dosing from 365 injections to 52. Can Onswik catch Novo Nordisk’s Awiqli?
Prime Medicine stock jumps after FDA clears PM647 gene-editing trial for alpha-1 antitrypsin deficiency

POPULAR NEWS

Representative image of a clinician reviewing skeletal imaging, illustrating Mirum Pharmaceuticals and Incyte’s zilurgisertib Phase 2 progress in fibrodysplasia ossificans progressiva and the rare disease treatment questions facing regulators.

Pharma & Biotech

Why Mirum Pharmaceuticals and Incyte’s zilurgisertib data could reset expectations in FOP treatment

June 15, 2026

Niagen Bioscience’s NB4168 has secured U.S. FDA Rare Pediatric Disease and European orphan designations as the company advances the experimental ataxia telangiectasia therapy toward human trials. Representative image.

Pharma & Biotech

Niagen wins twin rare-disease designations, but can NB4168 turn nicotinamide riboside evidence into a medicine?

July 14, 2026

Representative image of biopharma laboratory research. Gilead Sciences and Merck’s latest Phase 3 updates highlight the promise of once-weekly HIV treatment with islatravir and lenacapavir, while raising fresh questions over Trodelvy’s lung cancer expansion strategy.

Pharma & Biotech

Gilead and Merck pipeline update reveals promise in HIV and pressure in oncology

June 9, 2026

Latest business and industry news

Coal India, HURL explore Sindri coal-to-urea project as Rs 69,346cr gasification push widens
DroneShield lands US$500m counter-drone procurement vehicle as US expansion accelerates
Adani Ports settles SEBI public-shareholding case for Rs 37.05 lakh as stock jumps 4.5%
Airbus says 500 A321neos can keep flying, but can it still hit its delivery target?
Gold Fields eyes Northern Star after Australian miner rebuffs approach

TAGS

AstraZeneca clinical trials Eli Lilly and Company European Medicines Agency FDA FDA approval immunotherapy Inc. Johnson & Johnson medical devices non-small cell lung cancer oncology precision oncology U.S. Food and Drug Administration United States Food and Drug Administration

About PharmaDeviceNews
Disclaimer
Editorial Policy
Privacy Policy
Contact Us

© 2026 PharmaDeviceNews.com. All rights reserved.